Evidence map›Paper›PMID 41394228›Full record

ArticleCureus2025

Biofilm Disruption Enhances Antimicrobial Therapy for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth.

Michael Ruscio, Gavin Guard, Darla O'Dwyer, Ray Darville, Hannah Klopf, Robert Abbott, Scott Spiridigliozzi

Abstract read
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael RuscioIntegrative Medicine, Ruscio Institute for Functional Health, Austin, USA.
Gavin GuardIntegrative Medicine, Ruscio Institute for Functional Health, Austin, USA.
Darla O'DwyerHuman Sciences, Stephen F. Austin State University, Nacogdoches, USA.
Ray DarvilleAnthropology, Geography and Sociology, Stephen F. Austin State University, Nacogdoches, USA.
Hannah KlopfOsteopathic Medicine, Ruscio Institute for Functional Health, Austin, USA.
Robert AbbottIntegrative Medicine, Ruscio Institute for Functional Health, Austin, USA.
Scott SpiridigliozziIntegrative Medicine, Ruscio Institute for Functional Health, Austin, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Small intestinal bacterial overgrowth (SIBO) and intestinal methanogen overgrowth (IMO) are forms of microbial dysbiosis linked to gastrointestinal as well as systemic symptoms and sequelae. Some patients prefer non-antibiotic treatment options, and thus, herbal antimicrobials are emerging as alternatives to rifaximin. Treatment with pharmaceuticals or herbals can be hindered via biofilm-related resistance. This retrospective chart review evaluated whether adding a biofilm disruptor to herbal antimicrobials enhanced SIBO/IMO eradication, as defined by standardized breath test criteria.  Methods Thirteen patients with SIBO, IMO, or both, as determined by lactulose breath testing, had previously been randomized in a clinical protocol to receive either herbal antimicrobials alone (n = 5, control group) or herbal antimicrobials combined with biofilm disruptors (n = 8, treatment group) over an 8-week period.  Results Hydrogen levels declined more in the treatment group compared with controls (-30.75 vs -11.40 ppm, within-group P = 0.007). Methane levels also decreased more in the treatment group than in controls (-26.38 vs -2.00 ppm, within-group P = 0.042). The SIBO eradication rate ranged from 60-100%, but did not differ significantly across groups. Neither group achieved eradication of IMO.  Conclusions Adding a biofilm disruptor to herbal antimicrobials was associated with significantly greater reductions in hydrogen and methane gas levels. While SIBO eradication rates with herbal protocols - both with and without biofilm agents - were comparable to those seen with rifaximin, the differences were not statistically significant; importantly, this was likely due to the small sample size. Larger prospective, controlled studies are needed to validate these findings and clarify the potential role of biofilm disruptors in the management of SIBO/IMO.

Indexed as

anti-biofilmdysbiosisgut microbiotaherbal therapiesintestinal methanogen overgrowthsibosmall intestinal bacterial overgrowth

Identifiers

PMID41394228
PMCPMC12701763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.